RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
BiosimilarsIP.com Legal provides analysis of legal decisions from federal courts and from the PTAB related to biologics and biosimilars.
-
-
On June 14, 2018, Senator Orrin Hatch of Utah, the co-author of the Hatch-Waxman Act, filed an amendment to the Hatch-Waxman Act in an...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On March 8, 2018, Amgen Inc. (“Amgen”) filed suit against Adello Biologics, LLC (“Adello”) in the District of New Jersey, alleging...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we recently covered, May 15, 2018, saw the FDA granting approval to Hospira (now a Pfizer subsidiary) for its Retacrit injection, a...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Lately, it has been very difficult to get diagnostic claims allowed without limiting the method steps to very specific components (e.g....
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. recently scored a victory in their ongoing dispute over a...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Biologic drugs are large molecules, such as therapeutic proteins, DNA vaccines, monoclonal antibodies, and fusion proteins, that are...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]